Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

24.07 -0.56 (-2.27%)
Streaming Delayed Price Updated: 12:07 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 374,909
Open 24.54
Bid (Size) 24.06 (3)
Ask (Size) 24.08 (2)
Prev. Close 24.63
Today's Range 24.06 - 24.62
52wk Range 22.01 - 33.71
Shares Outstanding 166,121,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
The Analyst Landscape: 7 Takes On Alkermes
Via Benzinga

Performance

YTD
-15.90%
-15.90%
1 Month
+1.35%
+1.35%
3 Month
-11.86%
-11.86%
6 Month
-13.63%
-13.63%
1 Year
-26.30%
-26.30%

More News

Read More
In a market where value is scarce, NASDAQ:ALKS offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Via InvestorPlace
6 Analysts Assess Alkermes: What You Need To Know
Via Benzinga
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
Via Chartmill
7 Analysts Assess Alkermes: What You Need To Know
Via Benzinga
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
Via Chartmill
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
Via Chartmill
Breaking Down Alkermes: 5 Analysts Share Their Views
Via Benzinga
ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
Via Chartmill
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
Via Benzinga
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Is NASDAQ:ALKS suited for growth investing?
Via Chartmill
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
Via Benzinga
Exploring NASDAQ:ALKS's growth characteristics.
Via Chartmill
Earnings Scheduled For February 15, 2024
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Amicus Therapeutics Stock Sees RS Rating Improve To 74
Via Investor's Business Daily
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Via InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.